Skip to main content

Omeros Corporation (OMER)

NASDAQ: OMER · IEX Real-Time Price · USD
7.97
+0.24 (3.11%)
After-hours:Oct 15, 2021 7:57 PM EDT
7.73
0.00 (0.00%)
At close: Oct 15, 4:00 PM
Market Cap472.59M
Revenue (ttm)86.63M
Net Income (ttm)-139.42M
Shares Out62.37M
EPS (ttm)-2.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,354,631
Open7.88
Previous Close7.73
Day's Range7.40 - 7.99
52-Week Range6.51 - 23.85
Beta1.17
AnalystsBuy
Price Target40.40 (+422.6%)
Est. Earnings DateNov 8, 2021

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HS...

IndustryPharmaceuticals
IPO DateOct 8, 2009
CEOGregory Demopulos
Employees277
Stock ExchangeNASDAQ
Ticker SymbolOMER
Full Company Profile

Financial Performance

In 2020, Omeros's revenue was $73.81 million, a decrease of -33.98% compared to the previous year's $111.81 million. Losses were -$138.06 million, 63.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Omeros stock is "Buy." The 12-month stock price forecast is 40.40, which is an increase of 422.64% from the latest price.

Price Target
$40.40
(422.64% upside)
Analyst Consensus: Buy

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised to cont...

6 hours ago - PRNewsWire

OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and En...

NEW YORK--(BUSINESS WIRE)-- #Omeros--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the “Comp...

1 week ago - Business Wire

OMER EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Omeros Corporation Investors with Losses to Inquire Ab...

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (...

1 week ago - PRNewsWire

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encoura...

LOS ANGELES, Oct. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation ("Ome...

1 week ago - PRNewsWire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER...

LOS ANGELES--(BUSINESS WIRE)---- $OMER #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...

1 week ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Inve...

BENSALEM, Pa.--(BUSINESS WIRE)---- $OMER #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) investors conc...

1 week ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encou...

LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.

1 week ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourag...

LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.

1 week ago - Business Wire

OMER INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire Abo...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (NASDAQ: OMER...

1 week ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

New York, New York--(Newsfile Corp. - October 1, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors ar...

2 weeks ago - Newsfile Corp

OMER Stock: Why Little-Known Omeros Is Absolutely Plunging Today

Today, some rather unfortunate news has come to light regarding one of Omeros' prospective drugs, taking OMER stock 40% lower. The post OMER Stock: Why Little-Known Omeros Is Absolutely Plunging Today a...

2 weeks ago - InvestorPlace

Here's why Omeros Corp shares are down 40% on Friday morning

The U.S. FDA notified Omeros Corporation (NASDAQ: OMER) that it identified deficiencies in the company's marketing application for Narsoplimab, Omeros disclosed in a press release this morning.   Shares...

2 weeks ago - Invezz

Here's Why Omeros Stock Is Tanking Today

The narsoplimab program hasn't proceeded as swimmingly as investors thought.

2 weeks ago - The Motley Fool

Do Options Traders Know Something About Omeros (OMER) Stock We Don't?

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

2 weeks ago - Zacks Investment Research

Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA's ongoing review of the company's B...

2 weeks ago - Business Wire

Why Omeros Stock Is Plummeting This Week

The biotech stock was part of a larger Wall Street sell-off.

2 weeks ago - The Motley Fool

Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates

Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Omeros: Q2 Earnings Insights

Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to ($0.46), which beat the esti...

2 months ago - Benzinga

Omeros Corporation Reports Second Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

2 months ago - Business Wire

Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 202...

2 months ago - Business Wire

Earnings Preview: Omeros (OMER) Q2 Earnings Expected to Decline

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients

Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-assoc...

4 months ago - Benzinga

Omeros' Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell tra...

4 months ago - Business Wire

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

Omeros (OMER) announces initial results from a phase I study of OMS906.

4 months ago - Zacks Investment Research

Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

4 months ago - Business Wire